Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

Lack of Rebound Disease Activity in Participants with Relapsing Multiple Sclerosis Following Placebo Run-out in the Tolebrutinib Phase 2b Trial

Author:Traboulsee, Anthony   Fox, Robert   Arnold, Douglas   Syed, Sana   Orogun, Larry   Dukovic, Deborah   Turner, Timothy   Reich, Daniel   Oh, Jiwon   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.006  

Author Institution:University of British Columbia, Vancouver, BC, Canada  Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH  NeuroRx Research and Montréal Neurological Institute, McGill University, Montreal, QC, Canada  Sanofi, Cambridge, MA  Sanofi, Bridgewater, NJ  National Institute of Neurological Disorders and Stroke, Bethesda, MD  St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada  

Effect of RIPK1 Inhibitor, SAR443820, on Serum Neurofilament Light Levels in Patients with Multiple Sclerosis: A Phase 2 Trial Design

Author:Montalban, Xavier   Kuhle, Jens   Fox, Robert   Vartanian, Timothy   Horakova, Dana   Filippi, Massimo   Roos, Ernest   Wallstroem, Erik   Atassi, Nazem   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.011  

Author Institution:Multiple Sclerosis Centre of Catalonia, Department of Neurology–Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain  Department of Neurology, University Hospital and University of Basel, Basel, Switzerland  Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH  Brain and Mind Research Institute, Weill Cornell Medicine, Cornell University, New York, NY  Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University, Prague, Czech Republic  Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy  Sanofi, Bridgewater, NJ  Sanofi, Cambridge, MA  

MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Patients with Relapsing Multiple Sclerosis: 2-Year Results

Author:Reich, Daniel   Traboulsee, Anthony   Syed, Sana   Xu, Zhixing   Turner, Timothy   Arnold, Douglas   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.012  

Author Institution:National Institute of Neurological Disorders and Stroke, Bethesda, MD  University of British Columbia, Vancouver, BC, Canada  Sanofi, Cambridge, MA  Sanofi, Bridgewater, NJ  NeuroRx Research and Montréal Neurological Institute, McGill University, Montreal, QC, Canada  

MRI, Efficacy, and Safety of Tolebrutinib in Patients with Highly Active Disease (HAD): 2-Year Data from the Phase 2b Long-term Safety (LTS) Study

Author:Fox, Robert   Oh, Jiwon   Arnold, Douglas   Syed, Sana   Xu, Zhixing   Turner, Timothy   Traboulsee, Anthony   Reich, Daniel   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.017  

Author Institution:Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH  St Michael's Hospital, University of Toronto, Toronto, ON, Canada  NeuroRx Research and Montréal Neurological Institute, McGill University, Montreal, QC, Canada  Sanofi, Cambridge, MA  Sanofi, Bridgewater, NJ  University of British Columbia, Vancouver, BC, Canada  National Institute of Neurological Disorders and Stroke, Bethesda, MD